Josep Mallolas

Sobre mi

Publicacions destacades

• Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort

  Autors:

  Trottier, B; Yang, CJ; Watanabe, D; Marchetti, G; Elbirt, D;

  (...)

  Heinzkill, M; Marongiu, A; Ramroth, J; D'Amato, L; Mallolas, J.

  Veure llistat complet d'autors

  Referència: Hiv Research And Clinical Practice 2025.

• The Role of Protease Inhibitors in HIV Treatment: Who Still Needs Them in 2025?

  Autors:

  Sempere, A; Alonso, R; Berrocal, L; Calvo, J; Foncillas, A;

  (...)

  Martinez, E; Miró, JM; de Lazzari, E; Mallolas, J; Ambrosioni, J.

  Veure llistat complet d'autors

  Referència: Infectious Diseases And Therapy 2025.

• Results of a fast-track HIV and hepatitis C screening protocol in Barcelona, Spain

  Autors:

  Chivite, I; Guilera, V; Callau, P; Aguiló, R; de Lazzari, E;

  Merino, MJ; Diaz, L; Carrodeguas, A; González-Sánchez, JL; Mallolas, J.

  Referència: Plos One 2025.

• Long-Term Health Outcomes of People with HIV Engaged in Chemsex: A Prospective Cohort Study on Drug Use, Sexual Behaviour, Sexually-Transmitted Infections and Vulnerability

  Autors:

  De la Mora, L; Laguno, M; Torres, B; Chivite, I; Foncillas, A;

  (...)

  Miquel, L; Blanch, J; Short, D; Mallolas, J; Martínez-Rebollar, M.

  Veure llistat complet d'autors

  Referència: Infectious Diseases And Therapy 2025.

• Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study

  Autors:

  Ugarte, Ainoa; De La Mora, Lorena; De Lazzari, Elisa; Chivite, Ivan; Fernandez, Emma;

  (...)

  Calvo, Julia; Blanco, Jose Luis; Martinez, Esteban; Mallolas, Josep; Torres, Berta.

  Veure llistat complet d'autors

  Referència: Journal Of Antimicrobial Chemotherapy 2024.

• Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations

  Autors:

  Inciarte, Alexy; de la Mora, Lorena; Huaier-Arriazu, Emilio; Torres, Berta; Canizares, Silvia;

  (...)

  Martinez, Esteban; Blanco, Jose Luis; Miro, J M; Martinez-Rebollar, Maria; Mallolas, Josep.

  Veure llistat complet d'autors

  Referència: Infectious Diseases And Therapy 2024.

• Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020

  Autors:

  Toyos, S; Berrocal, L; González-Cordó, A; Inciarte, A; de la Mora, L;

  (...)

  Blanco, JL; Martínez, E; Miró, JM; Mallolas, J; Torres, B.

  Veure llistat complet d'autors

  Referència: Eurosurveillance 2023.

• PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement

  Autors:

  Laguno, M; Ugarte, A; Martinez-Rebollar, M; Sobrino, Y; Font, G;

  (...)

  Rojas, J; Cordón, E; Blanco, JL; Martínez, E; Mallolas, J.

  Veure llistat complet d'autors

  Referència: Enfermedades Infecciosas Y Microbiologia Clinica 2023.

• Immunological and virological findings in a patient with exceptional post-treatment control: a case report

  Autors:

  Climent, Nuria; Ambrosioni, Juan; Gonzalez, Tania; Xufre, Cristina; Casadella, Maria;

  (...)

  Grau-Exposito, Judith; Mallolas, Josep; Alcami, Jose; Sanchez-Palomino, Sonsoles; Miro, Jose M.

  Veure llistat complet d'autors

  Referència: Lancet Hiv 2023.

• COVID-19 in patients with HIV: clinical case series

  Autors:

  Blanco, JL; Ambrosioni, J; Garcia, F; Martínez, E; Soriano, A;

  Mallolas, J; Miro, JM.

  Referència: Lancet Hiv 2020.

Projectes destacats

• A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected Adults.

  Investigador/a principal: Josep Mallolas Masferrer

  Finançador: Fundació Clínic per a la Recerca Biomèdica

  Codi: 2021-003868-27

  Durada: 01/01/2024 - 31/12/2026